Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

Trial Profile

Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs JTX 2011 (Primary) ; Nivolumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ICONIC
  • Sponsors Jounce Therapeutics
  • Most Recent Events

    • 13 Nov 2017 According to a Jounce Therapeutics media release, preliminary efficacy data expected in 1H 2018.
    • 09 Aug 2017 Enrollment has commenced in the phase II Part D portion of this trial according to a Jounce Therapeutics media release.
    • 06 Jun 2017 Safety and PK results (n=25), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top